Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone.
- Trial name
- NCT04912271
- Testing
- Granisetron transdermal patch, Palonosetron, Aprepitant
- Volunteers
- 140 people
- Sponsor
- Fudan University
Male Breast Cancer, Nausea and Vomiting
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy.
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00343863
- Testing
- palonosetron hydrochloride, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Washington
Colon Cancer
Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting
This study is designted to know optimal dose of Ramosteron to control for chemotherapy induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and clinilcal parameters using Rhodes Index.
- Trial name
- NCT02076529
- Testing
- Ramosetron 0.3mg, Ramosetron 0.45mg, Ramosetron 0.6mg
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Chonnam National University Hospital
Cervical Cancer, Nasopharyngeal Cancer
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly…
- Conditions
- Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting
- Trial name
- NCT05564286
- Testing
- Fosaprepitant, tropisetron, Dexamethasone
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shantou University Medical College
Leukemia, Lymphoma
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
The purpose of this trial is to determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with…
- Trial name
- AMENO-2 (NCT00415103)
- Testing
- Aprepitant, Palonosetron, Granisetron
- Where
- 5 sites in Spain
- Volunteers
- 196 people
- Sponsor
- PETHEMA Foundation
Neoplasms, Child
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
Chemotherapy-induced nausea and vomiting, sleep quality and pain are the common symptoms experienced by children with cancer. These symptoms significantly devastate the children's quality of life.
- Conditions
- Neoplasms, Child, Nausea, Vomiting
- Trial name
- NCT04853303
- Testing
- Hypnosis VR
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Chemotherapy-induced Nausea and Vomiting, Adverse Event
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant…
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer
- Trial name
- NCT03668639
- Testing
- Akynzeo, Dexamethasone
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Christina Ruhlmann
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for…
- Conditions
- Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05417867
- Testing
- Biospecimen Collection, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mayo Clinic
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors
RATIONALE: Mindfulness relaxation, a technique to help patients quiet their thoughts and relax their bodies before and during chemotherapy, may reduce or prevent nausea and vomiting.
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT00086762
- Testing
- MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management
- Where
- 9 sites in United States
- Volunteers
- 474 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Cancer
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
1. Primary Objective: To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2.
- Trial name
- NCT00636805
- Testing
- Palonosetron (Aloxi) and Dexamethasone
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
- Trial name
- OLN-EME (NCT04232423)
- Testing
- Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Emesis
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
For breast cancer patients receiving chemotherapy regimens, the use of a validated emesis (nausea and vomiting) risk calculator will provide superior anti-emetic (nausea and vomiting) control compared with "standard" anti-emetic…
- Trial name
- ER11-02 (NCT01913990)
- Testing
- Dexamethasone, Ondansetron, Aprepitant, Arm A: Standard Anti-emetic regimen
- Where
- Canada
- Volunteers
- 323 people
- Sponsor
- Ottawa Hospital Research Institute
Chemotherapy-induced Nausea and Vomiting
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
Chemotherapy induced nausea and vomiting (CINV) is one of the most distressing toxicities of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy (HEC) use.
- Trial name
- PRaCTiCE (NCT03219710)
- Testing
- Ondansetron, Dexamethasone, Aprepitant
- Where
- India
- Volunteers
- 240 people
- Sponsor
- All India Institute of Medical Sciences
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone.
- Trial name
- NCT02517021
- Testing
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 405 people
- Sponsor
- Helsinn Healthcare SA
Lymphoma, Non-Hodgkin
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented.
- Trial name
- NCT01843868
- Testing
- Standard anti-emetics in conjunction with R-CHOP
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Chemotherapy-induced Nausea and Vomiting, Lung Cancer
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
Chemotherapy induced nausea and vomiting (CINV) is a common adverse effect in treatment of cancer, which influences the quality of life and adherence to treatment of patients and leads to dehydration, malnutrition and even death.
- Trial name
- NCT03571126
- Testing
- Olanzapine
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Zunyi Medical College
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
At present, the clinical studies of 5-HT3RA are aimed at nausea and vomiting induced by single-day chemotherapy, but there are many chemotherapy schemes that require multi-day administration in clinical practice.
- Trial name
- NCT04472143
- Testing
- Granisetron Transdermal Delivery System
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Chemotherapy-induced Nausea and Vomiting
Prevalence of Delayed Chemotherapy Associated Nausea
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.
- Trial name
- CINrate (NCT04342780)
- Where
- Switzerland
- Volunteers
- 172 people
- Sponsor
- Antje Koller